





# SPOTLIGHT ON STAKEHOLDER SUCCESS

Getting to zero harm in controlled substance prescribing: Increasing the accuracy of prescription compliance monitoring through enhanced drug testing support

	<b>PATIENT</b>	<b>ENHANCED SAFETY</b>	<p>The number of drug screen orders in the ambulatory setting with appropriate confirmatory testing increased by 45.5% (53% to 98.5%) after implementing a drug screening option with an automated reflex.</p> <p>135-fold increase in opiate/benzodiazepine compliance testing enabling a 3-fold increase in the number of patients receiving comprehensive and appropriate controlled substance testing and prescription monitoring, thus increasing the likelihood of detecting dangerous opioid and benzodiazepine drug combinations and detecting compounds present at concentration below the cutoff of screening immunoassay</p>
	<b>CLINICIAN</b>	<b>INCREASED CONFIDENCE</b>	<p>New test features within the prescription compliance panels, such as auto-reflex to confirmation testing and a specimen integrity check, enables earlier and enhanced insights for clinical decision-making. Including, identification of false positives in 20% of presumptive positive urine drug screens and 4% of specimens identified as diluted, which could potentially lead to false negative results.</p> <p>“The laboratory consultation service has been tremendously helpful. They are responsive and thorough in addressing my general, as well as patient-specific questions. Knowing I have this resource provides another layer of confidence and comfort in interpreting challenging drug testing cases and caring for my patients.”</p> <p>- Dr. Kutaiba Tabbaa, Director, UH Parma Comprehensive Pain Program</p>
	<b>HEALTH SYSTEM / ADMINISTRATION</b>	<b>MITIGATED HOSPITAL RISK</b>	<p>35% increase (from 2020 to 2022) in UH Healthcare System physicians that are compliant with the urine drug testing recommendations, as outlined in national prescribing guidelines, with continued improvements made year over year.</p> <p>“The updated testing options our lab has been able to offer as part of our controlled substance monitoring program have been a tremendous help in decreasing the risk to our patients and providers. The definitive (confirmatory) results deliver actionable information to our providers, allowing them to meaningfully engage in the care of their patients. In addition to the testing options, the educational materials simplify the test selection process by efficiently guiding providers to the appropriate test for their patient’s specific circumstances.”</p> <p>- Edward Kay (RN), Team Lead, Quality Improvement RN, Clinical Risk Management &amp; Patient Safety</p>
	<b>PAYOR</b>	<b>REDUCED HEALTHCARE COSTS</b>	<p>113% increase in the number of physician offices providing appropriate opiate/benzodiazepine prescription compliance monitoring.</p> <p>Approximately a 25% reduction in opiate/benzo confirmatory drug test costs, attributed solely to moving testing in house.</p>